π-Icosa™ AAV Serotype Screening Platform
With its proprietary π-Icosa™ High-capacity and High-precision AAV serotype screening platform PackGene aims to screen higher infective and higher tissue-specific AAV serotypes for clinical trial development, which can greatly reduce the dosage and production cost of AAV-based gene drug while increasing safety and efficacy.
Advantages：
- Higher library capacity
- Higher precision AAV-serotype screening
- Improves the AAV targeting with the lower dosing to increase safety and efficacy
Interested in our AAV services? Please contact us for a free consultation or submit a request for a quotation.
Intellectual property:
Three patents are pending.
Screen the tissue-targeting AAVs to improve the efficiency
- Library＞1 billion mutants
- Screens efficient AAVs which specifically target muscle, brain, etc.
